Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
UT Southwestern faculty awarded CPRIT grants to combat cancer

UT Southwestern faculty awarded CPRIT grants to combat cancer

InnoPharma receives FDA approval for generic DACOGEN

InnoPharma receives FDA approval for generic DACOGEN

HICCC receives $18 million grant from the National Cancer Institute

HICCC receives $18 million grant from the National Cancer Institute

Suggestions for successful breast feeding from nurse midwifery program

Suggestions for successful breast feeding from nurse midwifery program

Scientists identify number of compounds to treat cancer could add to anti-malarial arsenal

Scientists identify number of compounds to treat cancer could add to anti-malarial arsenal

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Researchers identify mutated forms of gene that encodes unregulated enzyme driving CML

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Dasatinib: Leukemia drug shows promise for treating skin, breast and other cancers

Viewpoints: Va. GOP's 'Medicaid charade'; Paul Ryan's health Rx for poverty; giving the sick unapproved drugs

Viewpoints: Va. GOP's 'Medicaid charade'; Paul Ryan's health Rx for poverty; giving the sick unapproved drugs

Natural killer cells can be used to combat acute lymphoblastic leukemia

Natural killer cells can be used to combat acute lymphoblastic leukemia

Research findings may lead to novel target for chemoresistant cancer cells

Research findings may lead to novel target for chemoresistant cancer cells

HDAC inhibitors may also be effective against kidney stones

HDAC inhibitors may also be effective against kidney stones

AEG-1 protein blocks effects of retinoic acid in leukemia and liver cancer

AEG-1 protein blocks effects of retinoic acid in leukemia and liver cancer

Researchers find crucial signaling pathway that helps HSCs to generate

Researchers find crucial signaling pathway that helps HSCs to generate

New approach to predict myeloma patients using calcium isotope analysis

New approach to predict myeloma patients using calcium isotope analysis

Epigenetics has a large say in blood formation

Epigenetics has a large say in blood formation

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Avillion initiates BOSULIF Phase 3 trial in patients with chronic phase Ph+ CML

Scientists solve key mystery in cancer research

Scientists solve key mystery in cancer research

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

CTI BioPharma's pacritinib granted FDA Fast Track designation for treatment of myelofibrosis

Immunosuppressive drugs increase risk of myeloid disorders among IBD patients

Immunosuppressive drugs increase risk of myeloid disorders among IBD patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.